疱疹性坏死性视网膜炎继发于氟轻松醋酸酯眼内植入。
Herpetic necrotizing retinitis following flucinolone acetonide intravitreal implant.
机构信息
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Saint Louis, Missouri, USA.
出版信息
Ocul Immunol Inflamm. 2011 Feb;19(1):72-4. doi: 10.3109/09273948.2010.520404. Epub 2010 Oct 31.
PURPOSE
To report a case of herpes simplex virus-induced herpetic necrotizing retinitis after placement of a flucinolone acetonide (Retisert) intravitreal implant.
DESIGN
Interventional case report.
METHODS
Retrospective chart review.
RESULTS
A 22-year-old male with idiopathic unilateral panuveitis since 2002 that was intolerant of systemic immunosuppressive therapy received a flucinolone acetonide implant 6 years later. Intraocular inflammation was completely quiescent until 1 year following the implant, when he developed retinitis. To the authors' knowledge, this is the first reported case of polymerase chain reaction-proven herpetic necrotizing retinitis following implantation of a Retisert device.
CONCLUSIONS
Although rare, herpetic necrotizing retinitis can occur in the setting of local ocular immunosuppression with the Retisert intravitreal implant. This potential infection should be considered in the face of recurrent uveitis following Retisert implantation.
目的
报告一例在玻璃体内注射氟轻松醋酸酯（Retisert）植入物后，单纯疱疹病毒引起的疱疹性坏死性视网膜炎。
设计
介入性病例报告。
方法
回顾性图表审查。
结果
一名 22 岁男性，2002 年起患有特发性单侧全葡萄膜炎，对全身免疫抑制治疗不耐受，6 年后接受了氟轻松醋酸酯植入物治疗。植入物后 1 年内眼内炎症完全静止，此后他出现了视网膜炎。据作者所知，这是首例经聚合酶链反应证实的在使用 Retisert 装置后发生的疱疹性坏死性视网膜炎。
结论
尽管罕见，但在使用 Retisert 玻璃体内植入物进行局部眼部免疫抑制的情况下，可能会发生疱疹性坏死性视网膜炎。在 Retisert 植入后出现葡萄膜炎复发的情况下，应考虑这种潜在感染。
Zotero 插件